Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results.

• Results Overview

  Upadacitinib combined with topical steroids was effective and safe for treating moderate-to-severe eczema over a 52-week period, with higher doses showing better improvement in symptoms.

• Study Summary

  Num Participants:

  901

  Study Type:

  Rct

  Control Group:

  Placebo + Topical Corticosteroids

  Efficacy End Points Treatment:

  {'EASI-75': 50.8, 'vIGA-AD 0/1': 33.5, 'WP-NRS improvement ≥4': 45.3}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected